Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis

Last updated: July 6, 2020
Sponsor: Corfu Headache Clinic
Overall Status: Completed

Phase

N/A

Condition

Chronic Pain

Pain

Oral Facial Pain

Treatment

N/A

Clinical Study ID

NCT04463875
Corfu HC
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention, by an observational, prospective real-world study in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • established diagnosis of episodic migraine with or without aura for more than one yearprior to study entry

  • evidence of 4-14 migraine days per month during the last trimester prior to screening

  • participants may had been either treatment- naive or not suitable for or had failedprevious migraine pharmacological prophylactic treatments

  • were able to fully understand protocol and study information provided by theinvestigators.

  • enrolled patients should take no other preventive treatment or use any other migraineprophylactic method during the three months before entering the study and throughoutthe study period.

Exclusion

Exclusion Criteria:

  • older than 50 years of age at migraine onset

  • evidence of MOH

  • pregnant or nursing females

  • history of tension-type, cluster or hemiplegic headache

  • history of severe anaphylactic reactions to any of the intervention's ingredients

  • evidence of severe systemic diseases

  • history or evidence of major psychiatric disorder.

Study Design

Total Participants: 113
Study Start date:
April 01, 2018
Estimated Completion Date:
May 31, 2020

Study Description

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention.

An observational, prospective real-world study. After a one-month baseline period, Vivinor® was introduced in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3). Secondary endpoints included changes in mean intensity of migraine and in days with use of acute migraine medications. Changes in scores of Migraine Disability Assessment questionnaire (MIDAS), Headache Impact Test-6 (HIT-6), Migraine Therapy Assessment questionnaire (MTAQ), MSQ-QOL (Migraine-Specific Quality of life questionnaire), HADS (Hospital Anxiety and Depression Scale) were also evaluated. Those with ≥50% reduction in monthly migraine days during T3 compared to BL were considered Vivinor®-responders.

Connect with a study center

  • Corfu HC

    Corfu, 49100
    Greece

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.